Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

To be part of this study, you would need to have non-small cell lung cancer that has spread. Your doctors must have confirmed that other specific treatments, like those for EGFR, ALK, or ROS1 gene changes, are not suitable for you first. Crucially, your cancer cells must show a high level of a protein called PD-L1 (at least 50%), which will be checked with a special test on a sample of your tumour.

You also need to be generally well enough to participate, meaning you can carry out most of your normal daily activities. You would need to be expected to live for at least three more months, and if you have HIV, it must be well-managed with your current medication. People with small cell lung cancer or mixed tumours containing small cell elements generally cannot join.

There are also some conditions that would prevent you from taking part. For example, if you have severe nerve damage in your hands or feet (peripheral neuropathy), certain serious eye conditions, or active inflamatory bowel disease. If you've had a recent serious heart or brain condition, or if you've already received other treatments for your metastatic lung cancer, including other immunotherapy drugs like anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, you would likely not be eligible. However, if you had these immunotherapies for an earlier, non-spread form of lung cancer more than a year ago, you might still qualify.

If you decide to join this study, you will be assigned to one of two groups: one receiving the combination of sacituzumab tirumotecan and pembrolizumab, and the other receiving pembrolizumab on its own. You will have regular visits to the hospital for your treatments, which are usually given through a drip (intravenously).

Throughout the study, you'll have various tests, including blood samples, scans, and physical examinations, to monitor your health and how the treatment is working. Doctors will carefully track any side effects you might experience. If your cancer appears to worsen after the initial treatment course, some participants may be offered additional cycles of pembrolizumab alone.

There will be regular follow-up appointments even after your main treatment period ends, to continue monitoring your health over time. The total duration of your participation in the study, including follow-up, could extend over several months or even years, depending on how you respond to treatment.